Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer
Authors
Keywords
-
Journal
Immunotherapy
Volume 5, Issue 7, Pages 677-681
Publisher
Future Medicine Ltd
Online
2013-07-05
DOI
10.2217/imt.13.54
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
- (2013) Amy E Moran et al. CURRENT OPINION IN IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term
- (2012) M Chmielewski et al. GENE THERAPY
- Induction of tumoricidal function in CD4+T cells is associated with concomitant memory and terminally differentiated phenotype
- (2012) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4+ T Cells into CD4+FoxP3+ T Regulatory Cells by Production of IFN-γ
- (2012) Shravan Madireddi et al. PLoS One
- CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe
- (2012) David E. Gilham et al. TRENDS IN MOLECULAR MEDICINE
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
- (2011) D.-G. Song et al. CANCER RESEARCH
- Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes
- (2011) A. Palazon et al. CANCER RESEARCH
- Science gone translational: the OX40 agonist story
- (2011) Andrew D. Weinberg et al. IMMUNOLOGICAL REVIEWS
- Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling
- (2011) Andreas A. Hombach et al. INTERNATIONAL JOURNAL OF CANCER
- Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function
- (2011) Jessica Ann Hernandez-Chacon et al. JOURNAL OF IMMUNOTHERAPY
- CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation
- (2011) David M Kofler et al. MOLECULAR THERAPY
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- OX40 is required for regulatory T cell–mediated control of colitis
- (2010) Thibault Griseri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Aldehyde Dehydrogenase-Expressing Colon Stem Cells Contribute to Tumorigenesis in the Transition from Colitis to Cancer
- (2009) J. E. Carpentino et al. CANCER RESEARCH
- Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel Form of 4-1BB Ligand Eradicates Established Tumors
- (2009) R. K. Sharma et al. CANCER RESEARCH
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right
- (2009) C. E. Ruby et al. JOURNAL OF IMMUNOLOGY
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started